Answers are grounded in this paper and cite their sources.
Background Lipid droplet (LD) accumulation in glial cells during the subacute-chronic phases of stroke drives neuroinflammation and impedes neurological recovery. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) effectively lower peripheral lipids, but whether they regulate cerebral lipid homeostasis and improve post-stroke rehabilitation remains unclear.Methods Using a mouse photothrombotic infarction model, mice received a single dose of evolocumab (PCSK9i) on days 1, 3 or 7 postinjury. Motor function was evaluated by grid-walking, cylinder and DigiGait tests. Dendritic plasticity, glial perilipin 2 (PLIN2, an LD marker), and ox-LDL levels were assessed by Golgi-Cox staining, immunofluorescence and ELISA. Oxidative stress and pro-inflammatory gene expression ( Il1b, Tnf and C3) were evaluated by malondialdehyde measurement and qPCR. Following ox-LDL exposure, LD accumulation, oxidative stress and the expression of Il1b, Tnf, C3 and S100a10 in BV2 microglia and primary astrocytes were assessed by BODIPY staining, dihydroethidium staining and qPCR. Conditioned medium collected from ox-LDL-exposed microglia and astrocytes after culture in ox-LDL-free medium was applied to HT22 neurons to assess indirect ox-LDL-mediated effects on neuronal viability and the expression of postsynaptic density protein 95 and synaptophysin. DiI-labelled ox-LDL (DiI-ox-LDL) was administered via tail-vein injection to trace its entry into peri-infarct tissue.Results Evolocumab administered at each tested time point facilitated motor recovery. Day 3 treatment enhanced dendritic plasticity and reduced peri-infarct glial LD accumulation, ox-LDL levels, oxidative stress and inflammatory responses. In vitro, ox-LDL induced glial LD accumulation, oxidative stress and inflammation, while conditioned media produced detrimental effect on HT22 neurons. In vivo tracing showed that DiI-ox-LDL crossed the disrupted blood–brain barrier and accumulated in peri-infarct microglia and astrocytes.Conclusion PCSK9i administered during the subacute phase of stroke promotes neurological recovery. This benefit may arise, at least in part, from suppressing ox-LDL-induced glial LD pathology, supporting its potential for post-stroke rehabilitation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: